Site USSUB1022 — Omaha, Nebraska

Site USSUB1022 is a clinical research site located in Omaha, Nebraska, United States 68130.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Site USSUB1022 has participated in 1 clinical trials.

Therapeutic areas: Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer.

Sponsors: Astellas Pharma Global Development, Inc..

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site USSUB1022?

Site USSUB1022 has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site USSUB1022 conducted?

Site USSUB1022 has 1 clinical trials on record. Their work covers Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer.

Is Site USSUB1022 accredited by Crixeo Health?

Site USSUB1022 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site USSUB1022?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.